Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V

Most orally bioavailable drugs on the market are competitive inhibitors of catalytic sites, but a significant number of targets remain undrugged, because their molecular functions are believed to be inaccessible to drug-like molecules. This observation specifically applies to the development of small-molecule inhibitors of macromolecular interactions such as protein-membrane interactions that have been essentially neglected […]

Read More
Learn More